Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Completed 4Terminated 2Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Large Granular Lymphocytic 1Leukemia, Hairy Cell 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Glioma 1Breast Neoplasms 1

Interventions

Rituximab 58Cyclophosphamide 40fludarabine phosphate 27fludarabine 21Lenalidomide 19Mycophenolic Acid 17idelalisib 16Antilymphocyte Serum 16Cyclosporine 15Tacrolimus 13Radiotherapy 13Filgrastim 13venetoclax 12umbralisib 12Whole-Body Irradiation 12Busulfan 12Bendamustine Hydrochloride 12ublituximab 11ibrutinib 11Methotrexate 11Peripheral Blood Stem Cell Transplantation 10Alemtuzumab 10obinutuzumab 9Melphalan 9Chlorambucil 8Bortezomib 8thymoglobulin 7ofatumumab 7Etoposide 7Clofarabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Leukemia, Lymphocytic, Chronic, B-Cell × Leukapheresis × Clear all
NCT06343376 2025-08-03

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Roswell Park Cancer Institute

Phase 1 Terminated
1 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01408043 2019-06-14

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Case Comprehensive Cancer Center

Phase NA Terminated
25 enrolled 15 charts
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡